STOCK TITAN

Insulet Corporation - $PODD STOCK NEWS

Welcome to our dedicated page for Insulet Corporation news (Ticker: $PODD), a resource for investors and traders seeking the latest updates and insights on Insulet Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Insulet Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Insulet Corporation's position in the market.

Rhea-AI Summary
Insulet Corporation launches Omnipod 5 Automated Insulin Delivery System in Germany, expanding its market presence. The system has shown improved clinical outcomes in the U.S., making it an attractive option for individuals with type 1 diabetes. Omnipod 5 is the first CE marked tubeless automated insulin delivery system that integrates with Dexcom G6 Continuous Glucose Monitoring System. The company aims to make Omnipod 5 available for the majority of its European customers by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none
-
Rhea-AI Summary
Insulet Corporation (NASDAQ: PODD) to present at three upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
conferences
-
Rhea-AI Summary
Insulet Corporation (NASDAQ: PODD) reported strong financial results for the second quarter of 2023. The company achieved a revenue of $396.5 million, up 32.4% compared to the prior year. Total Omnipod revenue increased by 33.2%, with U.S. Omnipod revenue up by 40.9% and International Omnipod revenue up by 16.0%. Gross margin improved by 320 basis points to 66.8%. Operating income was $31.1 million, compared to an operating loss of $26.7 million in the prior year. Net income was $27.3 million, compared to a net loss of $35.0 million in the prior year. Adjusted EBITDA was $61.3 million, a significant increase from $27.6 million in the prior year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.63%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
Insulet Corporation

Nasdaq:PODD

PODD Rankings

PODD Stock Data

12.98B
69.53M
0.31%
103.67%
4.46%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ACTON

About PODD

insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down